Premium
Preparation, characterization, and sonodynamic antitumor effect of the folate receptor targeted FA‐EN‐β‐CD containing hematoporphyrin in vitro
Author(s) -
Wang Chuanjin,
Du Fuqiang
Publication year - 2020
Publication title -
drug development research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.582
H-Index - 60
eISSN - 1098-2299
pISSN - 0272-4391
DOI - 10.1002/ddr.21657
Subject(s) - hematoporphyrin , sonodynamic therapy , chemistry , phototoxicity , folate receptor , in vitro , pharmacology , microbiology and biotechnology , apoptosis , biochemistry , photodynamic therapy , cancer , cancer cell , medicine , biology , organic chemistry
To improve water solubility, reduce phototoxicity and increase the tumor‐targeting ability of hematoporphyrin (Hp) as a sonosensitizer for sonodynamic therapy under ultrasonic conditions, a novel folate receptor (FR)‐targeted, folate‐conjugated ethylenediamine‐β‐cyclodextrin (FA‐EN‐β‐CD) containing Hp (FA‐EN‐β‐CD‐Hp) was constructed. β‐Cyclodextrin containing Hp (β‐CD‐Hp) was also established as a nontargeted control. The inclusion efficiencies of Hp in FA‐EN‐β‐CD‐Hp and β‐CD‐Hp were determined to be 90.4 ± 2.7% (wt/wt) and 92.5 ± 3.4% (wt/wt), respectively. Growth inhibition rates in HepG‐2 cells in vitro were assessed upon ultrasound exposure. The results indicated that the growth inhibition rates of FA‐EN‐β‐CD‐Hp, β‐CD‐Hp, and F‐Hp (Hp: 150 μg/ml) reached 96.4 ± 3.6%, 53.4 ± 3.4%, and 48.2 ± 2.8%, respectively. These results indicated that FA‐EN‐β‐CD‐Hp is a promising drug delivery system in the field of sonodynamic cancer therapy.